Travere Therapeutics, Inc. TVTX Business Segments — External research and development
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept tvtx:ExternalResearchAndDevelopment.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s business segments — external research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s business segments — external research and development?
- Travere Therapeutics, Inc. (TVTX) reported business segments — external research and development of $27.73M in Q1 2026.
- How has Travere Therapeutics, Inc.'s business segments — external research and development changed year-over-year?
- Travere Therapeutics, Inc.'s business segments — external research and development increased by 24.0% year-over-year, from $22.36M to $27.73M.
- What is the long-term trend for Travere Therapeutics, Inc.'s business segments — external research and development?
- Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s business segments — external research and development has grown at a -6.2% compound annual growth rate (CAGR), from $129.7M to $107.04M.
- What does business segments — external research and development mean?
- This metric tracks expenditures paid to third-party organizations, such as contract research organizations or clinical trial sites, to support the development of the company's drug pipeline. It highlights the company's reliance on external partnerships to advance late-stage clinical programs.